DAWN CH Newsletters 2016

November 2016

Latest DAWN regional user group – South Region
DAWN patient View Button for a concise patient summary
Enhance your communication with timed messages from DAWN
Expand your capabilities with DAWN
NICE reverses decision on CDF leukaemia drug after price drop
Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera
Ofatumumab shows promise as consolidation therapy for CLL

October 2016

Work Smarter – DAWN Version 7.9.59
Important Support and Troubleshooting information for your DAWN AC system
How to record visit notes in DAWN including historical cards
Expand your capabilities with DAWN
NICE rejects Imbruvica for non-Hodgkin’s lymphoma
More Patient Education, Communication May Improve Myeloproliferative Neoplasm Care
AbbVie and Roche’s leukaemia drug venetoclax nears EU market

September 2016

Work smarter – Version 7.9.57
Resetting your DAWN password – help and guidance
New questionnaires to improve patient information recording and save time
Using DAWN with Internet Explorer Version 9 and 10
Expand your capabilities with DAWN
AbbVie’s venetoclax set for early access in UK
Family History Not Associated With Disease Progression in MGUS
Imbruvica® (ibrutinib) now available for some patients in Scotland with rare, aggressive and incurable blood cancers

August 2016

Work smarter – Version 7.9.57
Resetting your DAWN password – help and guidance
New questionnaires to improve patient information recording and save time
Using DAWN with Internet Explorer Version 9 and 10
Expand your capabilities with DAWN
AbbVie’s venetoclax set for early access in UK
Family History Not Associated With Disease Progression in MGUS
Imbruvica® (ibrutinib) now available for some patients in Scotland with rare, aggressive and incurable blood cancers

July 2016

DAWN Messaging – Promoting effective healthcare team communication
Checking your DAWN outbound interface
Fast and efficient electronic patient referrals
Support and trouble-shooting for your DAWN CH system and interfaces
Expand your capabilities with DAWN
Early intervention could prevent myeloma from taking root
Acute myeloid leukemia has at least 11 different subtypes
Added benefit of idelalisib drug not proven for patients with CLL

June 2016

Work Smarter – DAWN Version 7.9.55
DAWN patient View Button for a concise patient summary
Fast and efficient patient referrals
Enhance your communication with timed messages from DAWN
Support and trouble-shooting for your DAWN CH system
Scientists detect gene networks likely to be shared by all CLL patients
Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance
EC approves Imbruvica for first-line treatment of patients with chronic lymphocytic leukaemia

May 2016

Support Desk Holiday Closures
Increasing efficiency with front screen tallies
DAWN Messaging – Promoting effective healthcare team communication
Customer Support Resources
NHS lacking in ‘essential’ blood cancer specialist nurses
In newly diagnosed CLL, mutation tests are advised

April 2016

Support Desk Holiday Closures
The importance of upgrading your DAWN CH system
Paperless Working – communications and referrals
LLS Welcomes FDA Approval of Venclexta to Treat Certain Chronic Lymphocytic Leukemias
Studies highlight exciting trends in prognostic markers, combinations for myelofibrosis
EU approval for Revolade for children with rare blood disorder

March 2016

Support Desk Holiday Closures
DAWN Score Cards – patient or healthcare professional-completed online disease activity questionnaires
Improve Communication with SMS/Email functionality from DAWN
Patient Demographics – Best Practice
Race May Influence Clinical Outcomes in Myeloproliferative Neoplasms
NICE turns down Janssen’s Imbruvica for CLL
Obinutuzumab/Venetoclax Combo Highly Effective in CLL

February 2016

Support desk holiday closures
Deceased patients – investigating Hold Monitor messages
Managing telephone calls within the DAWN system
Demographics interfacing
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Ibrutinib Improves CAR T-cell Function, Efficacy in Leukemia
Lipids Involved in Cause of Myeloma in One of Three Patients

January 2016

DAWN Messaging – Promoting effective healthcare team communication
Why results are highlighted red in the history panel
Recommendations for your DAWN system: live and test
DAWN CH enables monitoring of a wide range of haematological disorders
Ofatumumab Approved as Maintenance Therapy for CLL
Risk Factors for Fatigue in Patients With Myeloproliferative Neoplasms Assessed
Prognostic Factors and the Impact of New Therapies